SLRX regains Nasdaq equity compliance; 1-year monitor under 5550(b)(1)

Salarius Pharmaceuticals (SLRX) announced it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), as confirmed by a Nasdaq Hearings Panel on October 10, 2025.

Rhea-AI Filing Summary

Salarius Pharmaceuticals (SLRX) announced it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), as confirmed by a Nasdaq Hearings Panel on October 10, 2025.

Nasdaq placed the company under a one-year Mandatory Panel Monitor starting October 10, 2025. If Salarius falls out of compliance with the equity standard during this monitoring period, Nasdaq staff will issue a delisting determination without allowing a compliance plan or cure period; Salarius would retain the right to request a hearing.

On October 13, 2025, the company issued a press release reiterating its compliance status.

Insights

Regulatory Compliance Analyst

Nasdaq compliance restored; a one-year monitor adds strict, binary downside if equity falls short again.

Salarius Pharmaceuticals, Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard, as of October 10, 2025. Nasdaq placed the company under a Mandatory Panel Monitor for one year starting that date. This indicates the listing has been preserved while subject to heightened oversight.

During the one-year monitor, if the Staff finds a new deficiency with the Equity Standard, the company will not receive time to submit a remediation plan or access the usual cure periods under Rule 5810(c)(3). Instead, Staff will issue a delisting determination, though the company can request a hearing with the Hearings Panel. This creates a stricter compliance regime with immediate procedural escalation upon any relapse.

What it means: listing risk is reduced today but becomes more binary over the next year. Key dependencies are maintaining stockholders’ equity at or above Nasdaq’s requirement throughout the monitor ending on or about October 10, 2026. Items to watch include any future disclosure affecting stockholders’ equity, and any Staff notices during the monitor. The company announced compliance in a October 13, 2025 press release (Exhibit 99.1).

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SLRX disclose in its 8-K?

Nasdaq’s Hearings Panel notified Salarius that it regained compliance with the minimum stockholders’ equity requirement under Rule 5550(b)(1).

When did Nasdaq confirm SLRX’s compliance?

On October 10, 2025, according to the company’s disclosure.

How long is SLRX under Mandatory Panel Monitor?

A one-year monitoring period beginning October 10, 2025.

What happens if SLRX falls out of equity compliance during monitoring?

Nasdaq staff will issue a delisting determination with no plan or cure period; Salarius may request a hearing.

Which Nasdaq rule is involved for SLRX?

Nasdaq Listing Rule 5550(b)(1), the minimum stockholders’ equity standard.

Did SLRX issue a press release?

Yes. A press release dated October 13, 2025 was filed as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 08:00 AM Learn about SEC filing dates

0001615219FALSE2450 Holcombe Blvd.Suite XHoustonTX00016152192025-08-152025-08-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10, 2025

SALARIUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware

001-36812

46-5087339

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

2450 Holcombe Blvd. Suite X Houston, TX

77021

(Address of principal executive offices)

(Zip Code)

(713) 913-5608
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class						Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001						SLRX			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 8.01. Other Events

On October 10, 2025, Salarius Pharmaceuticals, Inc. (“Salarius”) received a letter from the Nasdaq Hearings Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying Salarius that it has regained compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard”), as required by the Hearings Panel.

Nasdaq further notified Salarius that it will be subject to a Mandatory Panel Monitor for a period of one year from October 10, 2025. If, within that one-year monitoring period, the Listing Qualifications Staff (the “Staff”) finds Salarius again out of compliance with the Equity Standard that was the subject of the exception, Salarius will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff will not be permitted to grant additional time for Salarius to regain compliance with respect to that deficiency, nor will the company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). Instead, the Staff will issue a delisting determination letter and Salarius will have the opportunity to request a hearing with the Hearings Panel.

On October 13, 2025, Salarius issued a press release announcing that that it had regained compliance with the Equity Standard. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release of Salarius Pharmaceuticals, Inc., dated October 13, 2025

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SALARIUS PHARMACEUTICALS, INC.

Date: October 14, 2025

By:

/s/ Mark J. Rosenblum

Mark J. Rosenblum Acting Chief Executive Officer Executive Vice President & Chief Financial Officer